When you hear the word epilepsy, what comes to mind? For many, it rsquo;s a vague image of someone having a seizure ndash; ...

using real-world data from children treated with RNS therapy across 27 pediatric epilepsy centers to support an expansion in indication for use; FDA submission anticipated in second half of 2025 ...

NeuroPace is known for its innovative RNS System, the first brain-responsive platform that provides personalized treatment to manage seizures in patients with drug-resistant epilepsy, potentially ...

“We are pleased by the interest in our recent financing and the confidence it shows in our mission to transform the lives of people suffering from drug-resistant epilepsy through RNS ® therap ...

CEO Joel Becker expressed satisfaction with the financing's reception and emphasized NeuroPace's mission to improve the lives of those with drug-resistant epilepsy through its RNS® therapy.

Q4 2024 Earnings Call Transcript March 4, 2025 NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.18, ...

In response to these suggestions, a core group of 24 RNs volunteered to receive additional education related to epilepsy and best-practice PEMU care. The education program for the core group was ...

NeuroPace Inc (NPCE) reports a 22% annual revenue increase and outlines strategic initiatives for continued growth in 2025.

“We have several ongoing clinical programs examining the RNS System in expanded patient populations and new indications in epilepsy that are expected to announce data or have regulatory events ...

RN reviews safety, expectations ... Buchhalter, PhD MD, is the former director of the pediatric epilepsy program in the Mayo Clinic Department of Neurology, Rochester, MN.

Fourth Quarter 2024 Financial Results Total revenue in the fourth quarter of 2024 grew 19% to $21.5 million, compared with $18.0 million in the fourth quarter of 2023. The Company’s revenue growth was ...